Literature DB >> 30485522

Transcellular traversal of the blood-brain barrier by the pathogenic Propionibacterium acnes.

Xuetao Lu1, Xianlong Qi1, Xiuli Yi1, Zhe Jian1, Tianwen Gao1.   

Abstract

BACKGROUND: Propionibacterium acnes (P. acnes) is an anaerobe commonly stay in the body as part of the commensal microbiota, and a dominant bacterium of the human skin and hair follicles. It has been found that this bacterium could participate in brain inflammation that causes Alzheimer's disease (AD) and Parkinson's disease (PD). But how P. acnes invade the brain remains elusive.
METHODS: We established the in vitro blood-brain barrier (BBB) model by culturing the HBMEC/D3 cell line on collagen-coated PFTE membrane. The BBB model was verified by the transepithelial electrical resistance (TEER) and horseradish peroxidase (HRP) permeability rate, and observed by the scanning electron microscope (SEM), transmission electron microscope (TEM), as well as confocal microscope. The P. acnes was then cocultured with the in vitro BBB model and the permeability of P. acnes was measured by counting the bacteria clones collected from the lower chamber of the model.
RESULTS: High local concentration of P. acnes invaded the in vitro BBB model through the transcellular traversal pathway. The permeability for P. acnes was increased by the treatment of lipopolysaccharide (LPS), but not mannitol. P. acnes invasion elevated the expression of cell adhesion molecules E-selectin, ICAM-1, and VCAM-1 in HBMEC cells.
CONCLUSION: P. acnes has the ability to penetrate the brain though transcellular invasion of the blood-brain barrier.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  P. acnes; blood-brain barrier; invasion; permeability; transcellular

Year:  2018        PMID: 30485522     DOI: 10.1002/jcb.28132

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  2 in total

Review 1.  Propionate and Alzheimer's Disease.

Authors:  Jessica Killingsworth; Darrell Sawmiller; R Douglas Shytle
Journal:  Front Aging Neurosci       Date:  2021-01-11       Impact factor: 5.750

2.  NU9056, a KAT 5 Inhibitor, Treatment Alleviates Brain Dysfunction by Inhibiting NLRP3 Inflammasome Activation, Affecting Gut Microbiota, and Derived Metabolites in LPS-Treated Mice.

Authors:  Lu Chen; Wenxiang Qing; Zexiong Yi; Guoxin Lin; Qianyi Peng; Fan Zhou
Journal:  Front Nutr       Date:  2021-07-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.